|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
|
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
MESALAZINE MAY INHIBIT THE METABOLISM OF THIOPURINE ANTINEOPLASTICS LIKE AZATHIPRINE, MERCAPTOPURINE
|
INCREASED POTENTIAL FOR HEPATOTOXICITY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
|
|
|
|
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
MESALAMINE MAY INHIBIT THE METABOLISM OF THIOPURINE ANTINEOPLASTICS LIKE AZATHIPRINE, MERCAPTOPURINE
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
OLSALAZINE MAY INHIBIT THE METABOLISM OF THIOPURINE ANTINEOPLASTICS LIKE AZATHIPRINE, MERCAPTOPURINE
|
5-AMINO SALICYLIC ACID INHIBITS THE METABOLISM OF THE DRUG LEADING TO INCREASED PLASMA LEVELS
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
|
|